AKT1 and metabolic dysfunction-associated steatotic liver disease: Specifically, the Pi3k/Akt pathway is dysregulated in T2DM and is also a promising target for NAFLD due to its regulation of downstream Mtor and Srebpc, which induce lipogenesis in the liver (Feng et al., 2022; Huang et al., 2018).